SEC Form 4 · accession 0001104659-26-084777
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul Efron
Director
Period of report
Jul 15, 2026
Accepted (ET)
Jul 17, 2026 · 9:56 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001567892
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Jul 15, 2026 | A | 4,406 | A | — | — | Ordinary Shares | 4,406 | 8,390 | D |
Explanation of responses
- F1Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.
- F2The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.
Remarks
This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.